Randomized trial demonstrates enhanced nucleic acid delivery in vitro using virus-like nanoparticles, suggesting improved gene therapy applications.
Efficient and safe delivery of nucleic acids remains a major challenge for clinical translation of gene therapies. Here, we report de novo-designed α-helical peptides that coassemble with lipids and nucleic acids to form core-shell, virus-like nanoparticles (VLNs). The peptides combine a cationic N-terminus for nucleic acid binding, an anionic C-terminus for lipid coordination, and pH-responsive residues that promote endolysosomal escape. The resulting VLNs achieved up to 91.2% mRNA transfection and 93.1% siRNA-mediated gene knockdown in vitro, outperforming Lipofectamine 2000. This work demonstrates a programmable, rational design strategy to produce virus-mimetic nanocarriers that address key extracellular and intracellular barriers in nucleic acid therapeutics.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: